vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Katapult Holdings, Inc. (KPLT). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $73.9M, roughly 1.2× Katapult Holdings, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 17.3%). Katapult Holdings, Inc. produced more free cash flow last quarter ($-12.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Katapult Holdings, Inc. is a U.S.-based fintech company that provides accessible point-of-sale lease-to-purchase solutions for consumers with limited or no traditional credit history. It partners with a wide network of e-commerce platforms and brick-and-mortar retail merchants across segments including electronics, furniture and home goods to offer flexible payment plans for customers to obtain needed products.
IOVA vs KPLT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $73.9M |
| Net Profit | — | $19.8M |
| Gross Margin | 67.4% | 15.6% |
| Operating Margin | -84.7% | -1.4% |
| Net Margin | — | 26.8% |
| Revenue YoY | 17.7% | 17.3% |
| Net Profit YoY | — | 307.3% |
| EPS (diluted) | — | $3.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $73.9M | ||
| Q3 25 | $67.5M | $74.0M | ||
| Q2 25 | $60.0M | $71.9M | ||
| Q1 25 | $49.3M | $71.9M | ||
| Q4 24 | $73.7M | $63.0M | ||
| Q3 24 | $58.6M | $60.3M | ||
| Q2 24 | $31.1M | $58.9M | ||
| Q1 24 | $715.0K | $65.1M |
| Q4 25 | — | $19.8M | ||
| Q3 25 | $-91.3M | $-4.9M | ||
| Q2 25 | $-111.7M | $-7.8M | ||
| Q1 25 | $-116.2M | $-5.7M | ||
| Q4 24 | — | $-9.6M | ||
| Q3 24 | $-83.5M | $-8.9M | ||
| Q2 24 | $-97.1M | $-6.9M | ||
| Q1 24 | $-113.0M | $-570.0K |
| Q4 25 | 67.4% | 15.6% | ||
| Q3 25 | 43.0% | 19.7% | ||
| Q2 25 | 5.5% | 15.5% | ||
| Q1 25 | -0.8% | 19.9% | ||
| Q4 24 | 68.7% | 11.8% | ||
| Q3 24 | 46.2% | 19.8% | ||
| Q2 24 | -0.8% | 16.9% | ||
| Q1 24 | — | 25.3% |
| Q4 25 | -84.7% | -1.4% | ||
| Q3 25 | -140.7% | 3.3% | ||
| Q2 25 | -189.8% | -2.0% | ||
| Q1 25 | -245.8% | -0.7% | ||
| Q4 24 | -117.5% | -7.7% | ||
| Q3 24 | -152.1% | -7.4% | ||
| Q2 24 | -327.6% | -4.5% | ||
| Q1 24 | -16464.6% | 5.8% |
| Q4 25 | — | 26.8% | ||
| Q3 25 | -135.3% | -6.7% | ||
| Q2 25 | -186.2% | -10.9% | ||
| Q1 25 | -235.5% | -7.9% | ||
| Q4 24 | — | -15.2% | ||
| Q3 24 | -142.7% | -14.7% | ||
| Q2 24 | -312.2% | -11.7% | ||
| Q1 24 | -15800.8% | -0.9% |
| Q4 25 | — | $3.69 | ||
| Q3 25 | — | $-0.94 | ||
| Q2 25 | $-0.33 | $-1.63 | ||
| Q1 25 | $-0.36 | $-1.23 | ||
| Q4 24 | $-0.24 | $-2.17 | ||
| Q3 24 | $-0.28 | $-2.05 | ||
| Q2 24 | $-0.34 | $-1.61 | ||
| Q1 24 | $-0.42 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $-38.1M |
| Total Assets | $913.2M | $107.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $22.4M | ||
| Q3 25 | $300.8M | $3.4M | ||
| Q2 25 | $301.2M | $3.7M | ||
| Q1 25 | $359.7M | $6.0M | ||
| Q4 24 | $323.8M | $3.5M | ||
| Q3 24 | $397.5M | $25.9M | ||
| Q2 24 | $412.5M | $33.7M | ||
| Q1 24 | $356.2M | $31.2M |
| Q4 25 | $698.6M | $-38.1M | ||
| Q3 25 | $702.3M | $-58.4M | ||
| Q2 25 | $698.5M | $-54.1M | ||
| Q1 25 | $767.9M | $-51.7M | ||
| Q4 24 | $710.4M | $-46.8M | ||
| Q3 24 | $773.5M | $-40.3M | ||
| Q2 24 | $768.5M | $-32.9M | ||
| Q1 24 | $680.0M | $-27.5M |
| Q4 25 | $913.2M | $107.9M | ||
| Q3 25 | $904.9M | $85.9M | ||
| Q2 25 | $907.4M | $90.6M | ||
| Q1 25 | $966.7M | $88.5M | ||
| Q4 24 | $910.4M | $93.2M | ||
| Q3 24 | $991.1M | $92.0M | ||
| Q2 24 | $964.3M | $106.6M | ||
| Q1 24 | $869.8M | $106.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-11.9M |
| Free Cash FlowOCF − Capex | $-61.9M | $-12.0M |
| FCF MarginFCF / Revenue | -71.3% | -16.2% |
| Capex IntensityCapex / Revenue | 10.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.60× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-11.9M | ||
| Q3 25 | $-78.7M | $4.0M | ||
| Q2 25 | $-67.4M | $-6.6M | ||
| Q1 25 | $-103.7M | $3.4M | ||
| Q4 24 | $-73.3M | $-32.6M | ||
| Q3 24 | $-59.0M | $-5.4M | ||
| Q2 24 | $-98.4M | $-628.0K | ||
| Q1 24 | $-122.3M | $2.0M |
| Q4 25 | $-61.9M | $-12.0M | ||
| Q3 25 | $-89.5M | $4.0M | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | $3.4M | ||
| Q4 24 | $-77.5M | $-32.6M | ||
| Q3 24 | $-61.3M | $-5.4M | ||
| Q2 24 | $-98.9M | $-653.0K | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | -16.2% | ||
| Q3 25 | -132.7% | 5.4% | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | 4.7% | ||
| Q4 24 | -105.1% | -51.8% | ||
| Q3 24 | -104.6% | -9.0% | ||
| Q2 24 | -317.9% | -1.1% | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | 0.0% | ||
| Q3 25 | 16.1% | 0.0% | ||
| Q2 25 | 12.4% | 0.0% | ||
| Q1 25 | 12.6% | 0.0% | ||
| Q4 24 | 5.7% | 0.1% | ||
| Q3 24 | 3.9% | 0.0% | ||
| Q2 24 | 1.4% | 0.0% | ||
| Q1 24 | 583.4% | 0.0% |
| Q4 25 | — | -0.60× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
KPLT
Segment breakdown not available.
